Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.54 |
| ▸ | ECE1 | P42892 | 8/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299580 | 0.90 | ERBB2 (0.55) | ERBB2ACEIL23RECE1EDNRA | |
| SCHEMBL31299590 | 0.89 | IL23R (0.58) | ERBB2ACEIL23R | |
| SCHEMBL31299583 | 0.86 | IL23R (0.55) | ERBB2IL23R | |
| SCHEMBL29658139 | 0.86 | ACE (0.58) | ERBB2ACEIL23RECE1MAGI3 | |
| SCHEMBL31299581 | 0.86 | IL23R (0.55) | ERBB2IL23RECE1 | |
| SCHEMBL30512698 | 0.84 | ERBB2 (0.65) | ERBB2IL23REDNRAMAGI3ERAP2 | |
| SCHEMBL31299582 | 0.84 | IL23R (0.59) | ERBB2IL23R | |
| SCHEMBL30622601 | 0.84 | KISS1R (0.58) | IL23R | |
| SCHEMBL30834730 | 0.83 | ACE (0.58) | ACEECE1MAGI3 | |
| SCHEMBL11151039 | 0.83 | MAGI3 (0.57) | ACEECE1EDNRAMAGI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192296-A | Polypeptide compound, pharmaceutical composition and application | 杭州禾泰健宇生物科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-119192296-A | Polypeptide compound, pharmaceutical composition and application | 杭州禾泰健宇生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |